Clinical Trial Update: Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency [Phase 2, Phase 3]

View source ↗

Summary

Phase II/III trial of Kamada-API, an alpha-1 proteinase inhibitor, in individuals with Alpha-1 antitrypsin deficiency has completed. The update notes the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency

Drugs mentioned

• Kamada-API (alpha-1 proteinase inhibitor)

Snippet

Sponsor: Kamada, Ltd. | Conditions: Alpha 1-Antitrypsin Deficiency | Phase 2, Phase 3 | Status: COMPLETED